About: Denileukin Diftitox     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : owl:Class, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
rdfs:label
  • Denileukin Diftitox
rdfs:subClassOf
Concept_In_Subset
Semantic_Type
  • Amino Acid, Peptide, or Protein
  • Pharmacologic Substance
Preferred_Name
  • Denileukin Diftitox
NSC_Code
  • 714744
UMLS_CUI
  • C0717670
CAS_Registry
  • 173146-27-5
Accepted_Therapeutic_Use_For
  • Cutaneous T-cell lymphoma
In_Clinical_Trial_For
  • B-cell chronic lymphocytic leukemia; metastatic kidney cancer; metastatic melanoma; Non-Hodgkins lymphoma; T-cell lymphoma
FDA_UNII_Code
  • 25E79B5CTM
Contributing_Source
  • FDA
ALT_DEFINITION
  • A drug used to treat cutaneous T-cell lymphoma that can bind the cytokine IL-2 and that has not responded to other treatment. It is also being studied in the treatment of other types of cancer. Ontak is made by combining a part of IL-2 with a bacterial toxin. The IL-2 part of the drug attaches to the cancer cells and then the toxin kills the cells. Ontak is a type of immunotoxin and a type of fusion toxin.NCI-GLOSS
PDQ_Open_Trial_Search_ID
  • 42325
PDQ_Closed_Trial_Search_ID
  • 42325
Legacy_Concept_Name
  • Denileukin_Diftitox
FULL_SYN
  • DAB(389)IL-2ABNCI
  • OntakPTNCI-GLOSSCDR0000520890
  • denileukin diftitoxPTNCI-GLOSSCDR0000045454
  • Interleukin-2 Fusion ToxinSYNCI
  • OntakBRNCI
  • Interleukin-2 Fusion ProteinSYNCI
  • LY335348CNNCI
  • Denileukin DiftitoxPTNCI
  • DAB389 Interleukin-2SYNCI
  • DAB389IL2ABNCI
  • DENILEUKIN DIFTITOXPTFDA25E79B5CTM
  • DAB389IL-2ABNCI
  • DAB389 Interleukin-2 ImmunotoxinSYNCI
  • DAB(389)-Interleukin-2SYNCI
DEFINITION
  • A cytotoxic recombinant protein consisting of interleukin-2 (IL-2) protein sequences fused to diphtheria toxin. The IL-2 protein sequence moiety of denileukin difitox directs the cytocidal action of diphtheria toxin to cells that express IL-2 receptors. After the toxin moiety is internalized into target IL-2 receptor-expressing cells, its catalytic domain catalyzes the transfer of the ADP-ribose moiety of NAD to a posttranslationally modified histidine residue of elongation factor 2 (EF-2), called diphthamine. This covalent modification inactivates EF-2 and disrupts polypeptide chain elongation, resulting in cell death. (NCI04)NCI
code
  • C1476
is someValuesFrom of
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 11 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software